Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

被引:6
作者
Cao, Huawei [1 ,2 ]
Sun, Zejia [1 ,2 ]
Wu, Jiyue [1 ,2 ]
Hao, Changzhen [1 ,2 ]
Wang, Wei [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Urol, Beijing, Peoples R China
[2] Capital Med Univ, Inst Urol, Beijing, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
关键词
Clear cell renal cell carcinoma; pancreatic metastasis; metastasectomy; systemic therapy; combinatorial treatment; SURVIVAL; CANCER; ATEZOLIZUMAB; RADIOTHERAPY; TOXICITY; EFFICACY; SAFETY;
D O I
10.3389/fsurg.2022.894272
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Clear cell renal cell carcinoma (CCRCC) is a common urological neoplasm, and even though surgical resection is effective for localized CCRCC, the prognosis of metastatic CCRCC is poor. Currently, there is a paucity of recognized effective therapeutic protocols for metastatic CCRCC. Case presentation: A 76-year-old Asian man underwent radical left nephrectomy for CCRCC 26 years ago; this patient visited our hospital with abdominal pain due to multiple abdominal metastases 24 years after the nephrectomy. After metastasectomy, he underwent targeted therapy combined with a programmed death receptor-1 (PD-1) inhibitor, and the current imaging results indicate remarkable tumor remission. Conclusions: Metachronous pancreatic metastasis from CCRCC after nephrectomy is rare, but clinicians and patients should not ignore this possibility. The combination of targeted therapy and immunotherapy can result in satisfactory outcomes in cases where metastatic CCRCC continues to progress despite metastasectomy and targeted therapy. The combination of local and systemic therapy can be an effective therapeutic protocol for metastatic CCRCC, but there is no consensus on suitable therapeutics.
引用
收藏
页数:6
相关论文
共 38 条
[1]   Metastasectomy of Sequential Asynchronous Metastatic Renal Cell Carcinoma to the Pancreas, Thyroid, Skin, Contralateral Kidney, and Lung with Cumulative Survival Beyond 10 Years: A Case Report and Clinicopathologic Review [J].
Alzahrani, Abdullah Mousa ;
Aggamy, Mohamed A. ;
Joudeh, Amani A. ;
Alabdullatif, Hanoof A. ;
Alzahrani, Hassan ;
Gomha, Mohamed A. .
AMERICAN JOURNAL OF CASE REPORTS, 2021, 22
[2]  
Bhindi B, 2019, EUR UROL, V75, P111, DOI [10.1016/j.eururo.2018.09.016, 10.1016/j.eururo.2018.11.021]
[3]   Distribution of metastatic sites in renal cell carcinoma: a population-based analysis [J].
Bianchi, M. ;
Sun, M. ;
Jeldres, C. ;
Shariat, S. F. ;
Trinh, Q. -D. ;
Briganti, A. ;
Tian, Z. ;
Schmitges, J. ;
Graefen, M. ;
Perrotte, P. ;
Menon, M. ;
Montorsi, F. ;
Karakiewicz, P. I. .
ANNALS OF ONCOLOGY, 2012, 23 (04) :973-980
[4]   Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis (vol 26, pg 2107, 2015) [J].
Bracarda, S. ;
Iacovelli, R. ;
Boni, L. ;
Rizzo, M. ;
Derosa, L. ;
Rossi, M. ;
Galli, L. ;
Procopio, G. ;
Sisani, M. ;
Longo, F. ;
Santoni, M. ;
Morelli, F. ;
Di Lorenzo, G. ;
Altavilla, A. ;
Porta, C. ;
Camerini, A. ;
Escudier, B. .
ANNALS OF ONCOLOGY, 2016, 27 (02) :366-366
[5]   Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences [J].
Buttigliero, Consuelo ;
Allis, Simona ;
Tucci, Marcello ;
Zichi, Clizia ;
Leone, Gianmarco ;
Di Stefano, Rosario Francesco ;
Redda, Maria Grazia Ruo ;
Ricardi, Umberto ;
Scagliotti, Giorgio Vittorio ;
Di Maio, Massimo ;
Filippi, Andrea Riccardo .
CANCER TREATMENT REVIEWS, 2018, 69 :215-223
[6]   Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study [J].
Cheung, Patrick ;
Patel, Samir ;
North, Scott A. ;
Sahgal, Arjun ;
Chu, William ;
Soliman, Hany ;
Ahmad, Belal ;
Winquist, Eric ;
Niazi, Tamim ;
Patenaude, Francois ;
Lim, Gerald ;
Heng, Daniel Yick Chin ;
Dubey, Arbind ;
Czaykowski, Piotr ;
Wong, Rebecca K. S. ;
Swaminath, Anand ;
Morgan, Scott C. ;
Mangat, Rupi ;
Keshavarzi, Sareh ;
Bjarnason, Georg A. .
EUROPEAN UROLOGY, 2021, 80 (06) :693-700
[7]   Rising incidence of renal cell cancer in the United States [J].
Chow, WH ;
Devesa, SS ;
Warren, JL ;
Fraumeni, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1628-1631
[8]   Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma [J].
Christensen, Bryce R. ;
Hajja, Yasmin M. ;
Koshkin, Vadim ;
Barata, Pedro C. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (02)
[9]   Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results [J].
Comandone, Alessandro ;
Vana, Federica ;
Comandone, Tiziana ;
Tucci, Marcello .
CANCERS, 2021, 13 (23)
[10]   Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 [J].
Escudier, Bernard ;
Motzer, Robert J. ;
Tannir, Nizar M. ;
Porta, Camillo ;
Tomita, Yoshihiko ;
Maurer, Matthew A. ;
McHenry, M. Brent ;
Rini, Brian, I .
EUROPEAN UROLOGY, 2020, 77 (04) :449-453